Ionizing radiation improves survival in mice bearing intracranial high- grade gliomas injected with genetically modified herpes simplex virus

Jeffrey D. Bradley, Yasushi Kataoka, Sunil Advani, Su Mi Chung, Ramin B. Arani, G. Yancey Gillespie, Richard J. Whitley, James M. Markert, Bernard Roizman, Ralph R. Weichselbaum

    Research output: Contribution to journalArticlepeer-review

    81 Scopus citations

    Abstract

    Malignant gliomas remain incurable with current interventions. Encouraging investigational approaches include the use of genetically modified herpes simplex-1 (HSV-1) viruses as direct cytotoxic agents. Combining attenuated HSV-1 with standard therapy, human U-87 malignant glioma xenografts grown in the hind limb or intracranially in athymic nude mice were exposed to ionizing radiation, in, oculated with genetically modified HSV R3616, or received both virus and radiation. The combination of virus with fractionated ionizing radiation suggests a synergistic action and results in reduced tumor volumes and longer survivals when compared with treatment with either modality alone.

    Original languageEnglish
    Pages (from-to)1517-1522
    Number of pages6
    JournalClinical Cancer Research
    Volume5
    Issue number6
    StatePublished - Jun 1999

    Fingerprint

    Dive into the research topics of 'Ionizing radiation improves survival in mice bearing intracranial high- grade gliomas injected with genetically modified herpes simplex virus'. Together they form a unique fingerprint.

    Cite this